Raytheon awarded $71 million in Navy contracts for missile systems
Mark Ragosa, the Chief Financial Officer of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), has sold shares of the company valued at $368,465, according to a recent filing. The transaction took place on March 20, 2025, involving the sale of 15,944 Class A Ordinary Shares at an average price of $23.11 per share. The sale comes as KNSA, currently valued at $1.7 billion, shows strong momentum with a robust financial health score of "GREAT" according to InvestingPro analysis.
In addition to the sale, Ragosa also acquired 15,944 shares through the exercise of share options at $12.97 per share, a move executed under a 10b5-1 trading plan established in September 2024. Following these transactions, Ragosa holds 23,382 shares directly. The transactions reflect a strategic adjustment to Ragosa’s holdings in the pharmaceutical company, which is headquartered in London. With impressive revenue growth of 56.6% and analyst targets suggesting significant upside potential, InvestingPro subscribers can access detailed insights and 8 additional ProTips about KNSA’s growth prospects.
In other recent news, Kiniksa Pharmaceuticals reported a preliminary revenue of $416.4 million for fiscal year 2024, marking a 79% increase compared to the previous year. This revenue surpasses both Goldman Sachs’s and Visible Alpha’s consensus estimates, which were $406.8 million and $411.2 million, respectively. Kiniksa has also provided guidance for Arcalyst revenue in fiscal year 2025, projecting between $560 million and $580 million. This forecast is notably higher than Goldman Sachs’s prediction of $529 million and modestly exceeds the consensus estimate. Goldman Sachs has maintained its Buy rating for Kiniksa, citing confidence in the company’s commercial strategy.
Additionally, Kiniksa announced plans to initiate a Phase 2/3 clinical trial for KPL-387, a treatment for recurrent pericarditis, expected to begin in mid-2025. The decision follows interactions with the U.S. Food and Drug Administration. Kiniksa aims to build on the success of its existing treatment, Arcalyst, which has generated over $800 million since its launch in 2021. The company is also developing KPL-1161 and has discontinued the development of abiprubart for Sjögren’s Disease. These developments reflect Kiniksa’s focus on addressing diseases with significant unmet needs, particularly in the cardiovascular space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.